Aerie Pharmaceuticals Inc. (AERI) is expected to grow earnings and revenues in the years ahead

Aerie Pharmaceuticals Inc. [AERI] stock is trading at $7.37, up up 8.38%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AERI shares have gain 1.10% over the last week, with a monthly amount drifted -10.88%, and not seem to be holding up well over a long-time horizon.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


On 4, August 2022, Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update. In a post published today on Yahoo Finance, Second Quarter Glaucoma Franchise Net Revenues of $33.3 Million, up 23% over Second Quarter 2021.

From an analyst’s perspective:

Aerie Pharmaceuticals Inc. [NASDAQ: AERI] stock has seen the most recent analyst activity on October 19, 2020, when BofA Securities downgraded its rating to a Underperform and also revised its price target to $9 from $14. On August 07, 2020, Needham reiterated its Buy rating and revised its price target to $26 on the stock. H.C. Wainwright reiterated its recommendation of a Buy and reduced its price target to $31 on May 07, 2020. BofA/Merrill started tracking with a Neutral rating for this stock on January 10, 2020, and assigned it a price target of $27. In a note dated January 09, 2020, SunTrust initiated an Buy rating and iterated a target price of $32 on this stock.

Aerie Pharmaceuticals Inc. [AERI] stock has fluctuated between $4.81 and $17.21 over the past year. Currently, Wall Street analysts expect the stock to reach $18.44 within the next 12 months. Aerie Pharmaceuticals Inc. [NASDAQ: AERI] shares were valued at $7.37 at the most recent close of the market. An investor can expect a potential return of 150.2% based on the average price forecast.

Analyzing the AERI fundamentals

Aerie Pharmaceuticals Inc. [NASDAQ:AERI] reported sales of 29.84 billion for the most recent quarter, which represents a growth of 29.60%. Gross Margin for this corporation currently stands at +86.17% with Operating Margin at -23.88%, Pretax Margin comes in at -38.23%, and Net Margin reading is -38.54%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.88 points at the first support level, and at 6.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.74, and for the 2nd resistance point, it is at 8.12.

Aerie Pharmaceuticals Inc. [AERI] reported earnings per share of -$0.66 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.65/share, meaning a difference of $-0.01 and a surprise factor of -1.50%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were $1.09 per share as compared to estimates of -$0.67 per share, a difference of $1.76 representing a surprise of 262.70%.

Ratios To Look Out For

For context, Aerie Pharmaceuticals Inc.’s Current Ratio is 2.70. Also, the Quick Ratio is 2.52, while the Cash Ratio stands at 1.12. Considering the valuation of this stock, the price to sales ratio is 1.68.

Transactions by insiders

We now turn our attention to insider trading, which in the past 3 months has resulted in 7 insider buyings of 48,746 shares and 1 insider sellings of 266 shares.